China Pharma Holdings (CPHI) Research & Development (2013 - 2026)
China Pharma Holdings' (CPHI) quarterly Research & Development came in at $83762.0 in Q1 2026, up 183.1% YoY from $29587.0 in Q1 2025, and down 55.92% on a QoQ basis from $190041.0 in Q4 2025.
China Pharma Holdings (CPHI) Research & Development (2013 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has 14 years of Research & Development data on file, last reported at $83762.0 in Q1 2026.
- Quarterly Research & Development rose 183.1% year-over-year to $83762.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $335076.0 (up 18.79% YoY) and the FY2025 annual result came in at $280901.0, down 1.07% from the prior year.
- Research & Development declined to $83762.0 in Q1 2026, from $190041.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $190041.0 in Q4 2025 to a low of $547.0 in Q4 2024.
- A 5-year average of $63208.4 and a median of $40321.0 in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development plunged 99.63% — and 2025, when it soared 34642.41%.
- Tracing CPHI's Research & Development over 5 years: stood at $27999.0 in 2022, then soared by 426.99% to $147552.0 in 2023, then sank by 99.63% to $547.0 in 2024, then soared by 34642.41% to $190041.0 in 2025, then plunged by 55.92% to $83762.0 in 2026.
- The last three Research & Development figures came in at $83762.0 (Q1 2026), $190041.0 (Q4 2025), and $40321.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 970.00 Mn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | -1.05 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 146.30 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 248.30 Mn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 326.70 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 92.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | China Pharma Holdings | 42.14 Mn | 41.84 Mn | 83,566.00 | 19,135.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 83,762.00 |
| Dec 31, 2025 | 190,041.00 |
| Sep 30, 2025 | 40,321.00 |
| Jun 30, 2025 | 20,952.00 |
| Mar 31, 2025 | 29,587.00 |
| Dec 31, 2024 | 547.00 |
| Sep 30, 2024 | 87,610.00 |
| Jun 30, 2024 | 164,334.00 |
| Mar 31, 2024 | 31,451.00 |
| Dec 31, 2023 | 147,552.00 |
| Sep 30, 2023 | 45,773.00 |
| Jun 30, 2023 | 23,747.00 |
| Mar 31, 2023 | 23,008.00 |
| Dec 31, 2022 | 27,999.00 |
| Sep 30, 2022 | 88,747.00 |
| Jun 30, 2022 | 15,063.00 |
| Mar 31, 2022 | 54,049.00 |
| Dec 31, 2021 | 54,048.00 |
| Sep 30, 2021 | 21,374.00 |
| Jun 30, 2021 | 53,456.00 |